Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$165 Mln
P/E Ratio
--
P/B Ratio
5.08
Industry P/E
--
Debt to Equity
0
ROE
-0.27 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.14
CFO
$-185.47 Mln
EBITDA
$-158.82 Mln
Net Profit
$-194.74 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
| 25.80 | -12.08 | 35.92 | 77.82 | 36.49 | 1.09 | -18.00 |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
| 5.57 | 29.93 | 64.72 | -77.09 | 10.67 | 5.47 | -52.76 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.71 | 10,257.64 | 20.82 | 23.13 | |
| 33.86 | 13,384.89 | -- | -28.77 | |
| 109.77 | 11,042.16 | 33.66 | 14.16 | |
| 74.93 | 9,430.55 | 41.53 | 19.71 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United... States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Address: Science Park, Karmiel, Israel, 2161401 Read more
President, CEO & Director
Mr. Dror Bashan
Senior VP, CFO, Treasurer & Corporate Secretary
Mr. Eyal Rubin M.B.A.
Headquarters
Karmiel
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Protalix Biotherapeutics Inc (PLX) stood at $ 86 Mln as on 30-Sep-24
The share price of Protalix Biotherapeutics Inc (PLX) is $2.37 (NYSE) as of 18-Mar-2025 15:41 EDT. Protalix Biotherapeutics Inc (PLX) has given a return of 36.49% in the last 3 years.
Protalix Biotherapeutics Inc (PLX) has a market capitalisation of $ 165 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Protalix Biotherapeutics Inc (PLX) is 5.08 times as on 17-Mar-2025, a 89% premium to its peers’ median range of 2.69 times.
Since, TTM earnings of Protalix Biotherapeutics Inc (PLX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Protalix Biotherapeutics Inc (PLX) and enter the required number of quantities and click on buy to purchase the shares of Protalix Biotherapeutics Inc (PLX).
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Address: Science Park, Karmiel, Israel, 2161401
The CEO & director of Mr. Dror Bashan. is Protalix Biotherapeutics Inc (PLX), and CFO & Sr. VP is Mr. Eyal Rubin M.B.A..
There is no promoter pledging in Protalix Biotherapeutics Inc (PLX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Protalix Biotherapeutics Inc (PLX) | Ratios |
|---|---|
|
Return on equity(%)
|
-30.88
|
|
Operating margin(%)
|
-16.99
|
|
Net Margin(%)
|
-21.03
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Protalix Biotherapeutics Inc (PLX) was $0 Mln.
$-0.09
(
